Publications by authors named "C A Wehling"
Background: The combination of gemcitabine and cisplatin (gem/cis) with the anti-PD-L1-antibody durvalumab was recently approved as first line therapy for biliary tract cancer (BTC) based on the results of the TOPAZ-1 trial.
Objective: We aim to analyse the feasibility and efficacy of the triple combination therapy in patients with BTC in a real-world setting and in correspondence with the genetic alterations of the cancer.
Methods: In this single-centre retrospective analysis, all patients with BTC and treated with durvalumab plus gem/cis from April 2022 to September 2023 were included.
Article Synopsis
- The COVID-19 pandemic led to a shift from traditional in-person medical education to e-learning, posing challenges for student motivation and engagement.
- A team of medical students and physicians created a series of interactive e-learning modules, simulating real patient scenarios within a 10-week curriculum to maintain relevance in clinical education.
- Student feedback indicated that the case-based, engaging format improved their motivation and allowed them to apply clinical knowledge effectively, suggesting this method can enhance learning even in socially isolated conditions.
Background: Anti-HBc only positive liver grafts may be suitable for HBV-naive recipients insofar as an appropriate infection prophylaxis is performed. Therefore, we investigated the effect of prophylactic regimens on HBV infection prevention and long-term outcome of anti-HBc-positive graft recipients.
Patients And Methods: This retrospective monocenter study consisted of a cohort of 1912 patients who underwent deceased donor liver transplantation at our transplant center between June 1987 and July 2019.
Purpose: This retrospective analysis focuses on treatment stage migration in patients with hepatocellular carcinoma (HCC) to identify successful treatment sequences in a large cohort of real-world patients.
Methods: 1369 HCC patients referred from January 1993 to January 2020 to the tertiary center of the Heidelberg University Hospital, Germany were analyzed for initial and subsequent treatment patterns, and overall survival.
Results: The most common initial treatment was transarterial chemoembolization (TACE, n = 455, 39.